Daratumumab

Daratumumab dosing is complex and typically follows a schedule that becomes less frequent over time. Dosing often depends on whether the drug is being used as a single agent or in combination with other therapies.

Multiple Myeloma (Intravenous Dosing)

For the IV formulation (Darzalex), the standard dose is usually 16 mg/kg of actual body weight. A typical schedule for combination therapy might look like this:

• Weeks 1 to 8: Once weekly (total 8 doses).
• Weeks 9 to 24: Every two weeks (total 8 doses).
• Week 25 onwards: Every four weeks until disease progression or unacceptable toxicity.

Multiple Myeloma (Subcutaneous Dosing)

For the SC formulation (Darzalex Faspro), a fixed dose of 1,800 mg is used regardless of the patient's body weight. The frequency (weekly, bi-weekly, or monthly) follows the same pattern as the IV formulation described above.

AL Amyloidosis (Subcutaneous Dosing)

The standard dose is 1,800 mg administered subcutaneously. The schedule typically involves weekly dosing for weeks 1-8, followed by every two weeks for weeks 9-24, and then every four weeks thereafter.

The safety and effectiveness of Daratumumab in pediatric patients (children under the age of 18) have not been established. There are currently no FDA-approved indications for Daratumumab in the pediatric population. Clinical trials in children are limited, and healthcare providers generally do not prescribe this medication for pediatric use outside of specific clinical research settings.

Renal Impairment

Based on population pharmacokinetic analyses, no formal dosage adjustments are required for patients with mild, moderate, or severe renal impairment. Daratumumab is a large protein and is not filtered by the kidneys in the same way small-molecule drugs are. However, patients with severe renal disease should be monitored closely for overall tolerance of the treatment regimen.

Hepatic Impairment

No dosage adjustments are necessary for patients with mild hepatic (liver) impairment. The effects of moderate to severe hepatic impairment on the pharmacokinetics of Daratumumab are not well-documented, as these patients were often excluded from clinical trials. Healthcare providers will use caution in patients with significant liver dysfunction.

Elderly Patients

No overall differences in safety or effectiveness have been observed between patients over 65 and younger patients. Dosage adjustments based solely on age are not required, though elderly patients are often more susceptible to certain side effects like upper respiratory tract infections.

Daratumumab is administered exclusively by healthcare professionals in a clinical setting (such as an infusion center or hospital). It is not available for self-administration at home.

• Pre-medication: To reduce the risk of infusion-related reactions (IRRs), patients are given several medications 1 to 3 hours before the Daratumumab dose. These typically include an intravenous corticosteroid (e.g., dexamethasone), an antipyretic (e.g., acetaminophen), and an antihistamine (e.g., diphenhydramine).
• Post-medication: Patients may be required to take oral corticosteroids for two days following the infusion to prevent delayed reactions. If a patient has a history of chronic obstructive pulmonary disease (COPD) or asthma, they may also be given short- and long-acting bronchodilators.
• Storage: The vials are stored in a refrigerator at 2°C to 8°C (36°F to 46°F) and must be protected from light. They should never be frozen or shaken.

If a scheduled dose of Daratumumab is missed, it should be administered as soon as possible. The subsequent dosing schedule should be adjusted accordingly to maintain the appropriate interval between doses. Patients should contact their oncology team immediately if they realize they have missed an appointment.

There is no known specific antidote for a Daratumumab overdose. Because the drug is administered by trained medical staff, the risk of a significant overdose is low. In the event of an accidental overdose, medical professionals will monitor the patient for any signs or symptoms of adverse reactions and provide appropriate supportive care. This may include managing severe infusion reactions or monitoring blood counts for signs of bone marrow suppression.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not attempt to adjust your schedule or skip pre-medications without direct medical guidance from your oncologist.

According to clinical trial data, the most frequently reported side effects associated with Daratumumab therapy include:

• Infusion-Related Reactions (IRRs): Occurring in nearly half of all patients during the first infusion. Symptoms include nasal congestion, cough, throat irritation, chills, and nausea. These are generally less common with the subcutaneous formulation.
• Fatigue: A profound sense of tiredness or exhaustion that does not always improve with rest. This can impact daily activities and quality of life.
• Nausea and Diarrhea: Gastrointestinal upset is common, though usually manageable with supportive care or over-the-counter medications as recommended by a doctor.
• Upper Respiratory Tract Infections: Including the common cold, sinus infections, and bronchitis. Daratumumab can lower the body's ability to fight off these common viruses.
• Pyrexia (Fever): Often occurring shortly after administration as part of an infusion reaction or as a general immune response.
• Hematologic Changes: Significant decreases in blood cell counts, specifically:
• Neutropenia: Low white blood cells, increasing the risk of infection.
• Thrombocytopenia: Low platelets, which can lead to easy bruising or bleeding.
• Anemia: Low red blood cells, causing shortness of breath and pale skin.

• Peripheral Edema: Swelling of the hands, ankles, or feet due to fluid retention.
• Hypertension: An increase in blood pressure, which may require monitoring or new medication.
• Muscle Spasms and Back Pain: General musculoskeletal discomfort is frequently reported in patients receiving combination therapies.
• Insomnia: Difficulty falling or staying asleep, often exacerbated by the corticosteroids given as pre-medication.
• Pneumonia: A more serious lung infection that requires prompt antibiotic or antiviral treatment.

• Atrial Fibrillation: An irregular and often rapid heart rate that can cause poor blood flow.
• Pancreatitis: Inflammation of the pancreas, characterized by severe abdominal pain.
• Hepatitis B Virus (HBV) Reactivation: In patients who have previously had Hepatitis B, the virus can become active again, potentially leading to liver failure or death.

> Warning: Stop taking Daratumumab and call your doctor immediately or seek emergency care if you experience any of the following:

• Anaphylaxis or Severe Infusion Reactions: Signs include difficulty breathing, wheezing, swelling of the face or throat, dizziness, or a rapid drop in blood pressure. This is a medical emergency.
• Severe Infections: A fever of 100.4°F (38°C) or higher, chills, or any signs of sepsis (confusion, extreme shivering, rapid heart rate).
• Signs of Liver Dysfunction: Yellowing of the skin or eyes (jaundice), dark urine, or severe pain in the upper right side of the abdomen.
• Unexpected Bleeding: Blood in the stool, nosebleeds that won't stop, or coughing up blood, which may indicate dangerously low platelet levels.

With prolonged use of Daratumumab, patients may experience persistent immune suppression. This can lead to an increased susceptibility to opportunistic infections (infections that occur more frequently or more severely in people with weakened immune systems). There is also a theoretical risk of secondary primary malignancies (new, unrelated cancers), although this is difficult to distinguish from the risks associated with the underlying cancer and other chemotherapy agents. Long-term monitoring of blood counts and immunoglobulin levels is standard practice.

As of the 2024-2026 clinical guidelines, Daratumumab does not carry an FDA Black Box Warning. However, it does have several "Warnings and Precautions" that are considered critical, particularly regarding infusion reactions and interference with blood bank testing. Healthcare providers must screen for Hepatitis B before starting treatment and monitor for reactivation throughout therapy.

Report any unusual symptoms, no matter how minor they seem, to your healthcare provider. Early intervention is key to managing the side effect profile of Daratumumab effectively.

Daratumumab is a potent biological agent that requires careful clinical management. Patients must be aware that this medication can significantly alter their immune system and interfere with certain laboratory tests. It is essential to carry a patient wallet card or wear a medical alert bracelet indicating that you are receiving Daratumumab, especially for emergency blood transfusion situations.

No FDA black box warnings for Daratumumab. While it is a high-risk medication, its safety profile is managed through standard clinical monitoring rather than a mandated Risk Evaluation and Mitigation Strategy (REMS) program.

Infusion-Related Reactions (IRRs)

Daratumumab can cause severe infusion reactions, including anaphylactic reactions. These are most common during the first infusion but can occur at any time. Medical facilities administering Daratumumab must have resuscitation equipment and emergency medications (like epinephrine and oxygen) readily available. If a reaction occurs, the infusion is slowed or stopped until symptoms resolve.

Interference with Blood Typing

This is a unique and critical warning. Daratumumab binds to CD38 on red blood cells (RBCs). This causes a false-positive result in the indirect antiglobulin test (indirect Coombs test). This interference can persist for up to 6 months after the last dose. It can mask the detection of antibodies to minor blood groups, making it difficult for blood banks to find a compatible match for a transfusion. Patients must have blood typing and screening performed BEFORE starting Daratumumab.

Neutropenia and Thrombocytopenia

The drug can cause a significant drop in white blood cell and platelet counts. This increases the risk of life-threatening infections and bleeding. Regular Complete Blood Counts (CBC) are required throughout treatment.

Hepatitis B Virus (HBV) Reactivation

In patients who are carriers of HBV, Daratumumab can cause the virus to become active again. This can lead to fulminant hepatitis and liver failure. Doctors will test for HBV before starting treatment and may prescribe antiviral medication as a preventive measure.

Patients undergoing treatment with Daratumumab require frequent laboratory monitoring to ensure safety and assess treatment efficacy:

• Complete Blood Count (CBC): Typically performed before every dose to monitor for neutropenia and thrombocytopenia.
• Liver Function Tests (LFTs): To monitor for signs of drug-induced liver injury or viral reactivation.
• Blood Glucose: Corticosteroids used as pre-medication can raise blood sugar levels, particularly in diabetic patients.
• Infection Monitoring: Patients are monitored for signs of viral infections, including Herpes Zoster (shingles). Prophylactic antiviral medication (like acyclovir) is often prescribed.

Daratumumab itself is unlikely to affect the ability to drive or operate machinery. However, the pre-medications (especially antihistamines like diphenhydramine) can cause significant drowsiness. Patients should not drive or operate heavy machinery until the effects of these pre-medications have worn off.

There are no known direct interactions between Daratumumab and alcohol. However, alcohol can worsen certain side effects like nausea and dehydration. Furthermore, alcohol can stress the liver, which may be problematic if the patient has underlying liver issues or is taking other hepatotoxic medications. Consult your doctor regarding safe alcohol consumption levels during treatment.

Daratumumab does not cause a physical withdrawal syndrome, so tapering is not typically required for the drug itself. However, if the patient is also taking high-dose corticosteroids as part of the regimen, these must be tapered slowly under medical supervision to avoid adrenal insufficiency. Treatment is usually continued until the disease progresses or the side effects become unmanageable.

> Important: Discuss all your medical conditions, including any history of lung disease or viral infections, with your healthcare provider before starting Daratumumab.

There are currently no specific drugs that are strictly contraindicated (forbidden) for use with Daratumumab based on direct biochemical interactions. However, the use of live vaccines is generally avoided during treatment because the drug suppresses the immune system, potentially allowing the vaccine-strain virus to cause a serious infection.

Immunosuppressants

Combining Daratumumab with other potent immunosuppressants (beyond the standard myeloma combinations) can cumulatively increase the risk of opportunistic infections. Healthcare providers must balance the need for multiple agents against the risk of profound lymphopenia (low lymphocytes).

Blood Transfusion Interference

While not a drug-drug interaction in the metabolic sense, Daratumumab has a serious interaction with the process of blood cross-matching. Because the drug binds to CD38 on red blood cells, it interferes with the indirect Coombs test used by blood banks. This can lead to delays in receiving blood products. To manage this, the blood bank must be notified that the patient is on Daratumumab so they can use specialized 'dara-blocking' methods (like using dithiothreitol-treated RBCs) to find compatible blood.

Laboratory Test Interference

Daratumumab is a monoclonal antibody that can show up on a Serum Protein Electrophoresis (SPEP) and Immunofixation (IFE) assay. These tests are used to monitor the 'M-protein' produced by myeloma cells. Because Daratumumab is itself a protein, it can be mistaken for the cancer's M-protein, potentially leading to a false impression that the cancer is not responding to treatment. Specialized assays are available to distinguish Daratumumab from the patient's endogenous M-protein.

There are no known interactions between Daratumumab and specific foods. Unlike many oral medications, Daratumumab is administered intravenously or subcutaneously, bypassing the digestive system's primary metabolic pathways. Patients are generally encouraged to maintain a high-protein, balanced diet to help the body repair tissues during cancer treatment.

• St. John's Wort: While Daratumumab is not metabolized by the CYP3A4 enzyme (which St. John's Wort induces), many of the drugs used in combination with Daratumumab (like certain proteasome inhibitors) may be affected.
• Immune-Boosting Herbs: Supplements like echinacea or astragalus that claim to 'boost' the immune system should be used with caution, as they could theoretically interfere with the intended immunosuppressive or immunomodulatory effects of the oncology treatment.
• Antioxidants: High doses of antioxidant supplements (Vitamin C, Vitamin E) are sometimes discouraged during chemotherapy and antibody therapy as they might protect the cancer cells from the oxidative stress intended by the treatment. Always consult your oncologist before starting any supplement.

As mentioned, the primary lab interactions involve:

1. 1Indirect Antiglobulin Test (Coombs Test): False positive, interfering with blood matching.
2. 2Serum Protein Electrophoresis (SPEP): Interference with M-protein quantification.

For each major interaction, the management strategy involves:

• Mechanism: Binding to non-target cells (RBCs) or physical presence of the antibody protein in the blood sample.
• Clinical Consequence: Delay in blood transfusion or inaccurate assessment of disease response.
• Management Strategy: Pre-treatment blood typing and the use of specialized laboratory techniques to bypass the interference.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Even 'natural' products can interfere with your cancer treatment plan.

There are very few absolute contraindications for Daratumumab, but they are critical for patient safety:

• Severe Hypersensitivity: Daratumumab is strictly contraindicated in patients with a history of severe hypersensitivity (e.g., anaphylaxis) to daratumumab or any of the excipients in the formulation. The subcutaneous formulation contains hyaluronidase, and patients with a known allergy to this enzyme must not receive Darzalex Faspro.
• Mechanism: An allergic reaction occurs when the immune system overreacts to the drug, releasing massive amounts of histamine and other chemicals that cause airway constriction and vascular collapse.

These are conditions where the drug may be used, but only after a careful risk-benefit analysis by the medical team:

• Active Infections: Because Daratumumab lowers white blood cell counts, starting treatment during an active, uncontrolled infection (such as systemic sepsis or active tuberculosis) could be life-threatening. The infection should generally be treated and stabilized first.
• Chronic Obstructive Pulmonary Disease (COPD) or Severe Asthma: Patients with these conditions are at a significantly higher risk for respiratory-related infusion reactions (e.g., bronchospasm). They require extra pre-medication and closer monitoring.
• Hereditary Fructose Intolerance: Some formulations may contain stabilizers that could be problematic for patients with rare metabolic disorders, though this is less common with modern monoclonal antibody preparations.

Patients who have had reactions to other monoclonal antibodies (such as rituximab or cetuximab) are not necessarily allergic to Daratumumab, as the protein sequences are different. However, they may be at a higher risk for infusion-related reactions in general. There is no known cross-reactivity between Daratumumab and common non-biologic drugs like penicillin or sulfa drugs.

> Important: Your healthcare provider will evaluate your complete medical history, including any past allergic reactions to medications or biological products, before prescribing Daratumumab.

Daratumumab is not recommended for use during pregnancy. It is classified as an IgG1 monoclonal antibody, and it is well-documented that human IgG antibodies cross the placental barrier, particularly during the second and third trimesters.

• Risks: Based on its mechanism of action, Daratumumab could cause fetal myeloid and lymphoid depletion (low blood cells in the fetus) and decreased bone density.
• Contraception: Females of reproductive potential should use effective contraception during treatment and for at least 3 months after the final dose. If a patient becomes pregnant while taking this drug, they must inform their doctor immediately.

It is not known whether Daratumumab is excreted in human milk. While many maternal IgG antibodies are present in breast milk, they are often degraded in the infant's gastrointestinal tract and have limited systemic absorption. However, because of the potential for serious adverse reactions in the breastfed child, healthcare providers typically advise patients to discontinue breastfeeding during treatment with Daratumumab.

Daratumumab is not approved for use in children. The safety and efficacy have not been established in patients under 18 years of age. Multiple myeloma is exceedingly rare in the pediatric population, and other CD38-positive pediatric cancers are currently being studied in clinical trials, but Daratumumab is not standard of care for these patients.

A large percentage of patients with multiple myeloma are over the age of 65. Clinical trials have shown that Daratumumab is generally safe and effective in this age group. No specific dosage adjustments are required. However, elderly patients should be monitored more closely for infections (especially pneumonia) and for the cardiovascular effects of the corticosteroids often given alongside Daratumumab.

No dosage adjustment is necessary for patients with renal impairment. Studies have shown that the pharmacokinetics of Daratumumab are not significantly altered by declining kidney function. This is particularly important because kidney damage is a common complication of multiple myeloma itself.

• Mild Impairment: No dosage adjustment is needed.
• Moderate to Severe Impairment: Daratumumab has not been extensively studied in patients with significant liver disease (Child-Pugh Class B or C). Since the liver is not the primary route of elimination for antibodies, major changes in drug levels are not expected, but the risk of toxicity may be higher due to the patient's overall fragile state.

> Important: Special populations require individualized medical assessment. Always disclose your full health status, including pregnancy plans or organ dysfunction, to your oncology team.

Daratumumab is a human IgG1κ monoclonal antibody that targets the CD38 protein. CD38 is a 45 kDa type II transmembrane glycoprotein that is expressed at high levels on the surface of multiple myeloma cells. It is also found at lower levels on normal lymphoid and myeloid cells and some non-hematopoietic tissues.

Upon binding to CD38, Daratumumab induces cell death through:

1. 1Fc-mediated effector functions: Including ADCC, ADCP, and CDC.
2. 2Direct effects: Induction of apoptosis through Fc-mediated cross-linking.
3. 3Enzymatic inhibition: CD38 has ectoenzyme activity; Daratumumab can inhibit this activity, which may alter the tumor microenvironment.

The pharmacodynamic effect of Daratumumab is characterized by a rapid reduction in CD38-positive plasma cells in the bone marrow and peripheral blood. This effect is dose-dependent. In clinical studies, a dose of 16 mg/kg resulted in sustained saturation of CD38 receptors and consistent depletion of tumor cells. The time to onset of response can vary, but many patients show signs of improvement within the first two cycles of therapy.

| Parameter | Value |

|---|---|

| Bioavailability | 100% (IV); ~70-80% (SC) |

| Protein Binding | Not applicable (it is a protein) |

| Half-life | ~18-21 days (at steady state) |

| Tmax | ~3 days (for SC formulation) |

| Metabolism | Catabolic proteolysis |

| Excretion | Reticuloendothelial system |

• Molecular Formula: C6472H10028N1744O2028S44 (approximate for the whole antibody)
• Molecular Weight: Approximately 148,000 Daltons (148 kDa).
• Solubility: Soluble in aqueous buffers (e.g., saline).
• Structure: A full-length human IgG1κ antibody consisting of two identical heavy chains and two identical light chains linked by disulfide bonds.

Daratumumab is classified as a CD38-directed cytolytic antibody. It is part of the broader class of targeted immunotherapy and monoclonal antibodies. Related medications include isatuximab (Sarclisa), which also targets CD38 but binds to a different epitope and has slightly different pharmacodynamic properties.